Page last updated: 2024-11-11

cyclo(leucyl-prolyl)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cyclo(leucyl-prolyl): structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cyclo(L-Leu-L-Pro) : A homodetic cyclic peptide composed from leucyl and prolyl residues. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7074739
CHEMBL ID508326
CHEBI ID133094
SCHEMBL ID2037800
MeSH IDM0413227

Synonyms (37)

Synonym
gancidin w
cyclo-l-leu-l-pro
cyclo(l-leu-l-pro)
CHEBI:133094
cyclo(l-pro-l-leu)
cyclo(leu-pro)
l-cyclo(leucyloprolyl)
l-leucyl-l-proline lactam
l,l-cyclo(leucylprolyl)
2873-36-1
l-cyclo(leu-pro)
cyclo(l-prolyl-l-leucyl)
(3s,8as)-3-(2-methylpropyl)hexahydropyrrolo[1,2-a]pyrazine-1,4-dione
cyclo(l-leucyl-l-prolyl)
cyclo(leucylprolyl)
CHEMBL508326
(3s,8as)-3-isobutyl-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione
cyclo-(l-pro-l-leu)
kqv8my059b ,
cyclo(-leu-pro)
maculosin 6
SCHEMBL2037800
(3s,8as)-3-isobutylhexahydropyrrolo[1,2-a]pyrazine-1,4-dione
AKOS024463311
mfcd00237617
cyclo l-pro-l-leu (fr. 1-6)
bdbm163709
cyclo(leucyl-prolyl)
J-017224
DTXSID40905040
AS-40794
pyrrolo[1,2-a]pyrazine-1,4-dione, hexahydro-3-(2-methylpropyl)-, (3s,8as)-
CS-0065365
EN300-28258032
rac-(3r,8ar)-3-(2-methylpropyl)-octahydropyrrolo[1,2-a]pyrazine-1,4-dione
cyclo(-l-leu-l-pro)
HY-P1939
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
marine metaboliteAny metabolite produced during a metabolic reaction in marine macro- and microorganisms.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
homodetic cyclic peptideA homodetic cyclic peptide is a cyclic peptide in which the ring consists solely of amino-acid residues in peptide linkages.
pyrrolopyrazine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)IC50 (µMol)50.00000.00050.742710.0000AID1801348
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
UDP biosynthetic processDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
'de novo' UMP biosynthetic processDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
pyrimidine ribonucleotide biosynthetic processDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
'de novo' pyrimidine nucleobase biosynthetic processDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
dihydroorotase activityDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
protein bindingDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
dihydroorotate dehydrogenase (quinone) activityDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
dihydroorotate dehydrogenase activityDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleoplasmDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
mitochondrionDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
mitochondrial inner membraneDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
cytosolDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
mitochondrial inner membraneDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID1543335Antibiofilm activity against Fusobacterium nucleatum ATCC 25586 assessed as inhibition of biofilm formation up to 96 ug/mL after 24 hrs by crystal violet staining based assay2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID1599335Antiviral activity against dengue virus2019European journal of medicinal chemistry, Aug-15, Volume: 176Recent update on anti-dengue drug discovery.
AID648930Antioxidant activity assessed as hydroxyl radical scavenging activity by electron spin resonance method2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Cyclic dipeptides exhibit potency for scavenging radicals.
AID1543365Antimicrobial activity against vancomycin-resistant Enterococcus faecalis measured after 24 hrs by agar-dilution method2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID1238341Antibacterial activity against Bacillus subtilis NCTC 2116 after 18 hrs by agar diffusion method2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Antibacterial activity of diketopiperazines isolated from a marine fungus using t-butoxycarbonyl group as a simple tool for purification.
AID1136963Inhibition of oxotremorine-induced tremor in NMRI mouse at 0.13 to 16 mg/kg, ip administered 1 hr prior to oxotremorine challenge1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Tripeptide analogues of melanocyte-stimulating hormone release-inhibiting hormone (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor.
AID400688Antibacterial activity against Staphylococcus aureus after 2 days by disk assay1996Journal of natural products, Mar, Volume: 59, Issue:3
Metabolites from an Antarctic sponge-associated bacterium, Pseudomonas aeruginosa.
AID1543364Inhibition of planktonic growth of Streptococcus mutans ATCC 25175 up to 96 ug/mL after 24 hrs relative to control2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID1238340Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 hrs by agar diffusion method2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Antibacterial activity of diketopiperazines isolated from a marine fungus using t-butoxycarbonyl group as a simple tool for purification.
AID1543336Antibiofilm activity against Porphyromonas gingivalis ATCC 33277 assessed as inhibition of biofilm formation up to 96 ug/mL after 24 hrs by crystal violet staining based assay2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID648929Antioxidant activity assessed as hydroxyl radical scavenging activity at 2.5 mM by electron spin resonance method2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Cyclic dipeptides exhibit potency for scavenging radicals.
AID1238342Antibacterial activity against Escherichia coli ATCC 25922 after 18 hrs by agar diffusion method2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Antibacterial activity of diketopiperazines isolated from a marine fungus using t-butoxycarbonyl group as a simple tool for purification.
AID400686Antibacterial activity against Bacillus cereus after 2 days by disk assay1996Journal of natural products, Mar, Volume: 59, Issue:3
Metabolites from an Antarctic sponge-associated bacterium, Pseudomonas aeruginosa.
AID1543354Antibiofilm activity against Streptococcus mutans ATCC 25175 assessed as inhibition of biofilm formation up to 96 ug/mL after 24 hrs by crystal violet staining-based assay2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens.
AID332429Displacement of [3H]substance P from NK1 receptor in human astrocytoma cells at 200 uM1994Journal of natural products, Apr, Volume: 57, Issue:4
Spiroquinazoline, a novel substance P inhibitor with a new carbon skeleton, isolated from Aspergillus flavipes.
AID648931Antioxidant activity assessed as superoxide radical scavenging activity at 2.5 mM by electron spin resonance method2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Cyclic dipeptides exhibit potency for scavenging radicals.
AID400687Antibacterial activity against Micrococcus luteus after 2 days by disk assay1996Journal of natural products, Mar, Volume: 59, Issue:3
Metabolites from an Antarctic sponge-associated bacterium, Pseudomonas aeruginosa.
AID1801348DCIP-linked Assay from Article 10.1111/cbdd.12530: \\Novel Diketopiperazine Dihydroorotate Dehydrogenase Inhibitors Purified from Traditional Tibetan Animal Medicine Osteon Myospalacem Baileyi.\\2015Chemical biology & drug design, Oct, Volume: 86, Issue:4
Novel Diketopiperazine Dihydroorotate Dehydrogenase Inhibitors Purified from Traditional Tibetan Animal Medicine Osteon Myospalacem Baileyi.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (6.25)18.7374
1990's2 (12.50)18.2507
2000's2 (12.50)29.6817
2010's10 (62.50)24.3611
2020's1 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.26 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index5.10 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.25%)6.00%
Case Studies1 (6.25%)4.05%
Observational0 (0.00%)0.25%
Other14 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]